Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2F2 | P24468 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070421 | 0.81 | NR2F2 (0.62) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL4713311 | 0.81 | ALDH1A1 (0.47) | NPSR1KDM4EMAPTMAPK1MEN1 | |
| SCHEMBL30560120 | 0.81 | NR2F2 (0.39) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL16094797 | 0.81 | NR2F2 (0.39) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL16094795 | 0.81 | NR2F2 (0.39) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL29501978 | 0.81 | NR2F2 (0.63) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL20299361 | 0.81 | NR2F2 (0.63) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL574167 | 0.80 | ALDH1A1 (0.60) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL30498501 | 0.80 | ALDH1A1 (0.60) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL761164 | 0.79 | NR2F2 (0.60) | NR2F2NPSR1KDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| EP-1590341-B1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1682532-B1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1682532-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | Warner-Lambert Company LLC (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1590341-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005042519-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE -3-KINASES (PI3K) | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004065378-A1 | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | PIK3CA, PIK3CD, PIK3R5 | NR2F2 2431/4885NPSR1 3742/4885KDM4E 2264/4885 |
| US-20040236084-A1 | E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders | CDK4, CCNA1, CCNI | NR2F2 2228/4885NPSR1 4330/4885KDM4E 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.